Y-Intercept (HK)’s Eikon Therapeutics EIKN Stock Holding History

Y-Intercept (HK)’s Portfolio EIKN Stock Details EIKN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$163K	Buy	+20,297	New	+$204K	﹤0.01%	1491

Other funds holding EIKN

Regents of the University of California Oakland, California $6.64B AUM 23.46% 1-Year Est. Return

Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Aspect Partners Fairfax, Virginia $264M AUM 15.76% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Y-Intercept (HK)'s EIKN Position: Q3 2026 in Review

Y-Intercept (HK) opened a new position in Eikon Therapeutics (EIKN) in Q3 2026: 20,297 shares worth $163K. The stake represents ﹤0.01% of the portfolio and ranks #1491 among its holdings.

14 funds tracked by Wall St. Rank hold EIKN as of Q3 2026.

Y-Intercept (HK) held 20,297 shares of Eikon Therapeutics worth $163K as of Q3 2026.
Eikon Therapeutics was a new Y-Intercept (HK) position in Q3 2026.
Eikon Therapeutics made up ﹤0.01% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1491 holding.
14 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.